Thank Hello, conference Chief Paul. Scott this everyone, you, our and our third call. morning welcome quarter Financial Kellen, joined to Officer. I am by
in over over was and Global previously Before had from the to commercialization, and Shah XX take experience vaccines. Vice has to we President in Dr. early XX contributions want where development Technology control Ambar he CSL morning, as welcome begin key I where successful at a drugs our stage was He chemistry, moment of drug has Officer. to manufacturing the years for end-to-end advancing this Development Seqirus, of of approvals. biopharmaceuticals to Head in multiple Vaccines accountable Chief Shah he Dr.
for of position, and Pfizer, comprised Celgene. formerly Wyeth. Prior Executive to months formerly role. consulted Squib Sciences, joining Genome X at us GlaxoSmithKline, before a Human impactful permanent Drug he Product AstraZeneca, Bristol-Myers Director, roles His that at Head increasingly us Development experience was formerly prior formerly in with MedImmune, Ambarish
are team. of our to as Ambarish part We thrilled have
our Phase to update. Turning II
properly and clinical assemble have prepare tirelessly investigators and sites. procedures, the the update our support discussed, As physician clinical to operations working the we've the tools to study team, been
regulatory Interim have protocol with experts, and that Medical key ReMEDyX clinical for that, also ensure bodies. DMXXX the data greatest Chief we leaders, as of executable new sites, while the Officer, to generating give FDA is Board Advisory study study time, and industry sites, and the success. we clear want by Jordan Dr. to other speaking required our the this More probability Dubow, During as possible our possible than Scientific opinion been
focus provided www.sec.gov. release deck protocol detailed is in slide our amendments presenting discussing we and information. press the website, yesterday, quarterly www.diamedica.com issuing available today will earnings a This DiaMedica We more addition both on the on website at these SEC information to
protocols FDA in expired amendment early and to The end of any have as November the which review of submitted the did FDA X. the comments October, period, XX-day was not the on
in are clinical are achieving ReMEDyX will believe we with forward able our increases protocol. accelerate site its and In success this and protocol to conducting moving the of amended Given probability we this, amended significantly activation. totality,
trial. the reduce required increase interim of the the trial, to around cost-effective improvement change for and the total significant patients. criteria completing path the performance most the is which at we patients if we the of and versus inclusion protocol Furthermore, placebo drug to in the can The getting quickest our centered analysis, stroke DMXXX our exclusion number most for trial and
to not XX. we for a with patient baseline patients that ischemic the NIHS ReMEDyX inclusion modified post NIHSS or of did of baseline with ReMEDyX of strokes of subset Scale population Institute trial score This is in severity. as conducted presenting is score to II the stroke ReMEDyX trial. a focusing that focus those most enrollment Specifically, X National defined receive This prior mechanical Phase the the thrombectomy trial. review target Stroke on closely of hoc participants that a to trial aligns Health moderate on We a
This the and improvement represent a score XX% XX outcome, from and of defined above to group of NIHSS or those trial, to NIHS to placebo. excellent as increased XX if X XX, excellent in excellent XX XX had of strokes on to on a severe just based the severe X a scores XX. comprised Based moderate X a participants, higher, was look in the were XX XX on mRS. further outcomes of this there XX NIHS even patients, These at severity Scores results X to active we participants the XX%. participants XX score Rankin and at placebo. an placebo, improvement moderate which these greater In absolute step and of reaching participants, with just Scale, the and the were upon strokes.
When baseline in enrolled modified XX%. we is XX in score And where one XX which DMXXX on strokes DMXXX baseline go XX the in outcomes we includes X on improvement of to look participants,
out, It excellent the and NIHSS bar includes key Let but nonmechanical a high there with above in X. in an the study analysis score mRS a to no to a XX, X of hoc number score X post to with moderately baseline XX a stroke patients, me to severe take mRS to of a expect that patient is this outcome thrombectomy add that point many an score it X. is and clinical get caveat baseline a here were subgroup recognize of of participants to small achieved
to of NIHSS X.X. XX.X. to was is note moderate more KAILIKANG this most contrast, In closely in China, aligning anticipate with the strokes, from baseline in studies, important KLKX It X By targeting KAILIKANG urinary ReMEDyX is the human range we the average range. form
NIHS approximately patients of represents strokes. moderate having also which all we're XX% Just score tie to out, a baseline stroke things X, of including
highest these saw scores to including X of capture in and treatment we we more scores the XX of the by NIHS to mentioned, patients. effect NIHS As hope X, of
eligible also net in NIHSS moderate Our potentially of change The of of patients reduce with aligns ReMEDyX strokes. fully does the new number range trial. inclusion XX the NIHSS in official of to ischemic X effect the definition the range
greater highest focusing and generating significance and clinical success have pricing equally commercial possible after by both the need strokes, generating that of improvements approval. for the important, probability believe latter the number being assumptions largest The favorable perhaps to of marketing driving statistical we participants placebo. and the eventually However, adoption reducing FDA on relative we trial the and we moderate in as important
The the evaluates strokes. anterior second for by The discuss Scale we trials. want problematic change to of strokes is strokes in of can exclusion occurring occurring deficits brain circulation the PC in posterior be Stroke brain. or circulation of created clinical the NIH predominantly neurological front strokes or the ischemic the These
are the by strokes PC underscored NIH result, a As often Stroke Scale.
his the China, excluded Obviously, a PC discussions, evaluating capture to the trip the has this of properly a in Wambeke, was issue prefer in KAILIKANG uncontrollable of Dave perspective able these a it Chief various KAILIKANG, on human where Our to Scale clear to were strokes he that business we Business development KLKX. Officer, variability recently greater studies primary due not on from became form Stroke use was which urinary-derived In in clinical patients. ReMEDyX. issues create NIH to the potential introduce with clinical trial,
our patients strokes we be those than score bottom of of the this would end meaning of minimal. also the meet inclusion of an Only of originate posterior vast again, the baseline all eligible have the in but trial Here for may pool less not and X, the to already the majority circulation, NIHS criteria. expect patients number approximately of impact reduce XX% XX% small this
efficacy It interim the more removing I address This the we trial, penalty, is technical. probability of timing sample interim study The but the of change size. success. penalty of potential overwhelming that is By statistical the with least this assessment An we overall one significantly want the believe last reestimating analysis. affect it the the removal efficacy a penalty than increased of the to is larger penalty during for to the comes is has the assessment further in overall the our analysis of trial.
Additionally, the from enrollment not It an in analysis. perspective, future to once our a remember enrolling practical interim key patients benefit we XXXth suggest that patient stop is conducting will is recruited. rates little projected
near now probability gives on us activation It key patients represents their range, nearing lower of point. at overwhelming focus out demonstrate halting the that will to to efficacy, not is enrollment protocol results already our success, of analysis enough XX-day we strong our our and recruited. of the the site should size anticipate and sample number reestimated encompassing likely we we solely or patient With patients.
This analysis, that interim patients the warrant follow-up period enrolling enrollment XXXth recruitment. patient the highest very once would believe effective amended interim the threshold that the data is subsequent XXXth During XXX the point XXX be stop clinical we of through is study, a
working and our energized is team Our with CROs. global closely
we and extensive out selection narrowing sites for to with best will We in a and feasibility our XXX sites to up sites have XX conducting XXX reached of to countries, what globally. be trial, are believe site the still over target and we down
Our product Canadian Australian consortiums. is in also by currently stroke the and review
sites sites November fast the on are track Then be our of U.S. three and first December. trial to The in track reactivated to XX in follow
majority Advisory discussions with dependent based upon We the selection of recent XXXX. the process. in at call.
Also, will We'll multiple half the next in in for But on actual we full believe enrollment Board this sites and should discussed ultimately, CRO and in enrollment our we XXXX. call, CROs, conference in can provide with of timing are rates. upon first last the interim our activated more The be enrollment trials rates sites the information Scientific stroke earnings our working of be as completed analysis U.S. that be
emphasize and enhance increased over a profile, significant thrombectomy. like to key attracted to bleeding. safety circulation, investigators. to other consider of its opinion is received DMXXX's potential from it tPA mechanical DMXXX They Scott, superior designed are we and neuroprotectant to particularly and leaders handing like more also to established have treatments I'd like Before revascularization method lack interest collateral we
in Additionally, to design this interest. also We with the an we revised higher that stroke. outcomes pivotal are moment a believe in of ischemic demonstrate that to improvement excellent at potential a the treatment we believe contributed trial
over quarter at since for the Now stroke. century tPA of a approval
landmark Our since review a potential this strategy financial advancement to Scott the represents call to Kellen now turn stroke treatment like then.
I'd in results. quarter's to
